Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7 -10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4 -6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.
Prostate cancer is the most frequently diagnosed malignancy and the second-leading cause of cancerrelated death among American men (Howe et al., 2001) . It is a multifactorial disease whose etiology may range from genetic factors to environmental components. The incidence and prognosis of prostate cancer varies with the age, ethnicity, country of origin, diet, and family history of the patients. For instance, the incidence of prostate cancer ranks first in black males compared with men of other ethnicities.
In the last 10 years, the genetic basis of prostate cancer has been extensively studied. Based on linkage analysis and case control studies, at least six prostate cancer susceptibility loci have been reported for hereditary prostate cancer (Ostrander and Stanford, 2000; Nwosu et al., 2001) . However, only one candidate prostate cancer susceptibility gene has been cloned within these loci very recently (Tavtigian et al., 2001) , and subsequent studies suggested that HPC2/ ECAC2 may play a more limited role in both sporadic and hereditary prostate cancer than expected Rokman et al., 2001; Wang et al., 2001) . This enforces the idea that hereditary prostate cancer is a very heterogeneous disease and that several genetic loci rather than any major susceptibility gene may predispose a large proportion of individuals to this disease.
Generally, genetic changes that either activate oncogenes or inactivate tumor suppressor genes can lead to the development and progression of cancers. Several genes have been implicated in the tumorigenesis of prostate cancer including c-myc, c-ErbB2/neu, TP53, APC, KAI1, GSTP1, PTEN, CD44, and the androgen receptor (AR) gene (Ozen and Pathak, 2000; Elo and Visakorpi, 2001) . AR plays an important role in prostate cancer (Montgomery et al., 2001) . The polymorphisms of CAG and GGN trinucleotide repeats in exon 1 of the androgen receptor gene have been associated with the development and progression of prostate cancer. However, somatic mutations of AR are not common in early stage prostate cancer and can account for about 20% of late stage prostate cancers (Marcelli et al., 2000) . TP53 mutations were reported in only 10 -20% of primary prostate cancers. Activation of RAS was rare in prostate cancer (Gumerlock et al., 1991) . The frequency of PTEN mutations is relatively high which was 30 -58% in metastatic carcinomas (Elo and Visakorpi, 2001) . The most frequent genomic alteration, thus far detected, is hypermethylation of the GSTP1 promoter region (490%) in prostate carcinoma (Lee et al., 1994) . It has been demonstrated that methylation of the GSTP1 promoter region results in loss of expression of GSTP1 in prostate cancer cells (Singal et al., 2001; Lin et al., 2001) . The methylation status of GSTP1 is currently used in clinical trials to act as a promising diagnostic marker for prostate carcinoma in the United States (Goessl et al., 2001; Cairns et al., 2001 ).
Epigenetic inactivation of tumor suppressor genes through DNA methylation contributes to tumorigenesis (Jones and Laird, 1999; Baylin and Herman, 2000; Esteller and Herman, 2002) . In prostate cancer, aberrant methylation of CpG islands of the CD44 gene, E-cadherin gene and estrogen receptor gene has been associated with tumor progression (Kito et al., 2001; Li et al., 2000 Li et al., , 2001 . Other genes that have been reported to be hypermethylated in their promoter regions in prostate cancer include the endothelin receptor B (EDNRB) gene, the AR gene and the caveolin-1 gene (Nelson et al., 1997; Pao et al., 2001; Nakayama et al., 2000; Cui et al., 2001) . Where tested, loss of expression of these genes was associated with CpG island hypermethylation, and expression could be restored after treatment with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor.
Recently, we and others (Dammann et al., 2000; Burbee et al., 2001 ) have cloned and characterized the Ras association domain family 1 (RASSF1) gene at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors (Kok et al., 1997; Sekido et al., 1998; Lerman et al., 2000; Wistuba et al., 2000) . One of the two major isoforms transcribed from this locus, RASSF1A, was absent in human lung and breast tumors due to promoter methylation (Dammann et al., 2000 Agathanggelou et al., 2001; Burbee et al., 2001) . Promoter hypermethylation, loss of heterozygosity and even homozygous deletions are the major mechanisms to inactivate this gene, while loss of function mutation is an infrequent event. Hypermethylation of the RASSF1A promoter region has been found in other primary human tumors (Lo et al., 2001; Dreijerink et al., 2001; Lee et al., 2001) . Ectopic expression of RASSF1A in lung cancer cells reduced colony formation, suppressed anchorage-independent growth and inhibited tumor formation in nude mice (Dammann et al., 2000; Burbee et al., 2001) . The homology of the RASSF1A gene with the mammalian Ras effector NORE1 suggests that the RASSF1A gene product may function in signal transduction pathways involving Ras-like proteins. It was shown that RASSF1 binds Ras in a GTP-dependent manner and that its overexpression induces apoptosis (Vos et al., 2000) . Our recent data indicate that the pro-apoptotic effect of RASSF1 may require heterodimerization with NORE1 and that RASSF1 itself binds to Ras only very weakly (Ortiz-Vega et al., 2002) . In addition, there is evidence for an association of both NORE1 and RASSF1 with the pro-apoptotic kinase MST1, and that this interaction is involved in apoptosis induced by activated Ras . The currently available data suggest that inactivation of RASSF1A is involved in the malignant progression of certain human cancers.
In the present study, we investigated the methylation status of RASSF1A in primary human prostate cancers and in a prostate cancer cell line to explore the candidacy of RASSF1A as a tumor suppressor gene in prostate carcinoma. All non-microdissected primary frozen prostatic adenocarcinoma tissues, 10 matching adjacent tissues and two prostate hyperplasia samples and pathological data were obtained from the tumor tissue bank of the Anatomic Pathology Department of the City of Hope National Medical Center (Duarte, CA, USA).
We analysed the methylation status of the RASSF1A gene's 5' CpG island and promoter region in human prostate cancer samples. We treated genomic DNA with sodium bisulfite, followed by methylation-specific PCR (MSP) and by a combined bisulfite restriction analysis (COBRA assay) to analyse the methylation status of this gene in 50 primary prostate cancer samples and two prostate hyperplasia tissues. Genomic Hela cell line DNA and A549 lung cancer cell line DNA have been shown to be unmethylated and completely methylated, respectively, in the RASSF1A promoter region in our previous works (Dammann et al., 2000) . These DNAs were used as negative and positive controls, respectively, in our methylation analysis. In MSP analysis (Figure 1a ), Hela DNA can only be amplified with unmethylated DNA-specific primers, while a PCR product from A549 DNA was obtained only using methylated DNA-specific primers. Sixty-nine per cent of primary prostate tumor samples (36 out of 52) showed methylation by MSP ( Figure 1a ; Table 1 ). We also obtained similar results by COBRA with TaqI digestion (34 out of 52, 65%, Figure 1b) . Results from four samples were inconsistent between these two methods. After direct sequencing of the respective PCR products (data not shown), we found that this disparity might largely arise from the endogenous limitations of the two methods. After bisulfite treatment, all unmethylated cytosines are converted to uracils, and then to thymines during subsequent PCR steps. All cytosines after subsequent PCR derive solely from 5-methylcytosines which are non-responsive to bisulfite. With COBRA and direct sequencing, our target sequence was a 205 bp PCR fragment which contains 16 CpG dinucleotides (Dammann et al., 2000) . TaqI can digest this fragment at CpG sites 6 and 16, only when the genomic DNA is methylated at these sites. Our primers for MSP were designed to detect the methylation status of four CpG sites (site numbers 9, 10, 11 and 12) and three other CpG sites outside of this fragment. Although in some cell lines all 16 CpG sites are completely methylated (Dammann et al., 2000) , in primary tumors these CpG sequences can be methylated to a somewhat lesser degree with occasional unmethylated sites interspersed between methylated CpGs. So, if CpG sites 6 and 16 are unmethylated, but CpG sites 9, 10, 11 and 12 are methylated, we will obtain negative results from COBRA, but positive results using methylation-specific PCR. In fact, both of these methods in isolation underestimate the methylation status of RASSF1A to some extent. Even when both methods came out with negative results, we observed that some other CpG sites were methylated by direct sequencing (data not shown). It has been shown that partial or complete methylation of a CpG island is usually associated with Frequent hypermethylation of the RASSF1A gene in prostate cancer L Liu et al a lack of gene expression, whereas active genes are associated with and probably require a complete lack of methylation in their 5' CpG island (Pfeifer et al., 1990) . In total, RASSF1A was methylated in 71% (37 out of 52) of primary prostate tumors combining the results from the two methods (Figures 1 and 2) . Interestingly, the frequency of methylation was higher in advanced tumors compared with early stage tumors (Table 1) . We included two benign hyperplasia samples in this study; neither of them showed methylation based on both MSP and COBRA. However, all tumors that metastasized (four out of four) or were poorly differentiated (five out of five) or were assigned a Gleason score higher than 8 (seven out of seven) were methylated at the promoter of RASSF1A. The samples with perineural invasion were more frequently methylated (24 out of 33, 77%) than tissues without perineural invasion (13 out of 21, 62%), although the difference did not reach statistical significance. In addition, Gleason 7 -10 cancers (25 out of 30, 83%) were significantly more methylated compared with Gleason 4 -6 cancers (11 out of 20, 55%; P=0.032 using Fisher's exact test). Our data did not meet the statistical criteria for significance for other pathoclinical parameters. It is possible RASSF1A may play an important role in prostate cancer progression.
Methylation of RASSF1A is generally rare in normal, non-neoplastic tissues (Dammann et al., 2000 Agathanggelou et al., 2001; Burbee et al., 2001; Dreijerink et al., 2001; Lee et al., 2001) . We analysed 10 normal prostate tissues in parallel with the matching tumors (Figure 2) . Four of them were partially methylated, but to a lower extent than the corresponding tumor tissue. This result might be attributable to tumor cell infiltration into the normal tissue, a common phenomenon in prostate cancer. This is supported by the fact that RASSF1A was methylated Figure 1 Methylation analysis of RASSF1A in primary human prostate cancers. (a) Methylation-specific PCR (MSP) analysis. Bisulfite modified genomic DNA extracted from primary human prostate tumors (T) were amplified with methylated DNA-specific primers (m) or with unmethylated DNA-specific primers (u). The methylated DNA-specific product (169 bp) and the unmethylated DNA-specific product (175 bp) were separated on 2% TBE agarose gels and visualized by ethidium bromide staining. Unmethylated Hela cell DNA and methylated A549 cell DNA were used as controls. (b) Combined bisulfite restriction analysis (COBRA) with TaqI digestion. PCR products from bisulfite-treated DNA obtained from primary tumors (T) were digested (+) or mock-digested (7) with TaqI. The digested products were resolved on 2% TBE agarose gels and visualized by ethidium bromide staining. Unmethylated Hela DNA and methylated A549 cell DNA were used as controls. The methylation status of the RASSF1A promoter region was determined by a bisulfite modification protocol (Clark et al., 1994; Dammann et al., 2000) . For combined bisulfite restriction analysis (COBRA; Xiong and Laird, 1997) , 100 ng of bisulfite-treated DNA was amplified with primer MU379 (5'-GTTTTGGTAGTTTAATGAGTTTAGGTTTTTT-3') and ML730 (5'-ACCCTCTTCCTCTAACACAATAAAACTAACC-3') in a 25 ml reaction volume containing 200 mM of each dNTP and Taq polymerase (Roche). The PCR conditions consisted of an initial incubation for 3 min at 958C, followed by 25 cycles of 20 s at 958C, 20 s at 568C and 40 s at 738C and finally a 4-min extension at 748C. One-fifth of the PCR products was used as templates for a semi-nested PCR with an internal primer ML561 (5'-CCCCA-CAATCCCTACACCCAAAT-3') and primer MU379 with similar conditions as described for the preceding PCR amplification, but for 30 cycles. The PCR products were purified using a QIAquick PCR purification kit (Qiagen). Twenty to 50 ng purified PCR products were digested with 10 units of TaqI (New England Biolabs) and resolved on 2% TBE agarose gels. For methylation specific PCR (MSP; Herman et al., 1996) , two sets of primers similar to those described by Burbee et al. (2001) were used to specifically amplify methylated and unmethylated DNA sequences, respectively, after treatment with sodium bisulfite. One hundred ng of bisulfite-treated genomic DNA was amplified with methylated DNA-specific primers, M210 (5'-GGGTTTTGCGAGAGCGCG-3') and M211 (5'-GCTAACAAACGCGAACCG-3') or unmethylated DNA-specific primers UM240 (5'-GGGGTTTTGTGA-GAGTGTGTTTAG-3') and UM241 (5'-TAAACACTAACAAACACAAACCAAAC-3') in a 100 ml reaction volume containing 200 mM of each dNTP and HotStar Taq polymerase (Qiagen). PCR was performed with an initial incubation for 15 min at 958C and followed by 45 cycles of denaturation at 948C for 30 s and annealing (648C for M210/M211, 628C for UM240/241) for 50 s and extension at 728C for 30 s. Fifteen ml of PCR products were resolved on 2% TBE agarose gels Frequent hypermethylation of the RASSF1A gene in prostate cancer L Liu et al only in those normal tissues whose cancerous counterparts also showed methylation (Figure 2 ).
Using MSP, we found that the promoter region of RASSF1A was highly methylated in the LNCaP cell line (Figure 3a) . We could only obtain a PCR product with methylated DNA-specific primers but not with unmethylated DNA-specific primers. To evaluate the expression of RASSF1A in LNCaP cells, we performed semi-quantitative RT -PCR. Our results showed that transcripts of RASSF1A were missing in LNCaP cells (Figure 3b) . To correlate the involvement of promoter hypermethylation with the loss of expression of RASSF1A, we treated the LNCaP cell line with different concentrations of 5-aza-2'-deoxycytidine, an Technologies) . RT -PCR was essentially performed as described (Dammann et al., 2000; Yoon et al., 2001) . One hundred ng of RNA was pre-associated with a lower primer from exon 4 of the RASSF1A gene (5'-TCC-TGCAAGGAGGGTGGCTTC). After the reverse transcriptase reaction, an upper primer from exon 1a (5'-TGGTGC-GACCTCTGTGGCGACTT) was used in the PCR. PCR conditions were 958C for 30 s, 608C for 30 s and 748C for 1 min, for 25 cycles for the RASSF1A gene and 18 cycles for the GAPDH gene. These cycle numbers were chosen because they were in the exponential range of product amplification. PCR products were separated on 2% TBE agarose gels, blotted, hybridized with a labeled probe, and visualized by autoradiography inhibitor of DNA methylation. As shown in Figure 3b , expression of RASSF1A was restored by 5-aza-2'-deoxycytidine treatment at a concentration of 2 mM or higher. This indicates that promoter methylation accounts for transcriptional repression of RASSF1A. We could not obtain enough good quality RNA samples from primary tumors to study expression levels. Our knowledge about chromosomal alterations at 3p is relatively scanty in prostate cancer (Dahiya et al., 1997) . Loss of sequences from the short arm of chromosome 8 is the most common allelic imbalance seen in this type of tumor. Frequent loss of heterozygosity at 3p21 has not been reported in prostate cancer. Nonetheless, we show here that the RASSF1A gene, previously implicated in several tumors with 3p21 allele loss, is very commonly targeted by methylation in prostate cancer. This may indicate that RASSF1A could play an important role as a prostate cancer suppressor gene and that focusing on LOH-rich regions of the genome may not pinpoint all tumor suppressor genes.
Novel approaches for the early detection and management of prostate cancer are urgently needed. Genetic and epigenetic alterations have been used in the detection of neoplastic cells in bodily fluids from several cancer types. The highest frequency of methylation in prostate cancer has been reported for the GSTP1 gene (Lee et al., 1994) . Since RASSF1A methylation is also very common (470% of the tumors analysed), analysis of RASSF1A methylation in urine of prostate cancer patients, along with GSTP1 methylation (Goessl et al., 2001; Cairns et al., 2001) , should become useful as a test in prostate cancer early detection and diagnosis. Simultaneous monitoring of the RASSF1A methylation status might aid prognosis by gauging the potential status of progression.
